Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Improved Preservation of Residual Beta Cell Function by Atorvastatin in Patients with Recent Onset Type 1 Diabetes and High CRP Levels (DIATOR Trial)
Background A recent r and omized placebo-controlled trial of the effect of atorvastatin treatment on the progression of newly diagnosed type 1 diabetes suggested a slower decline of residual beta cell function with statin treatment . Aim of this secondary analysis was to identify patient subgroups which differ in the decline of beta cell function during treatment with atorvastatin . Methodology /Principal Findings The r and omized placebo-controlled Diabetes and Atorvastatin ( DIATOR ) Trial included 89 patients with newly diagnosed type 1 diabetes and detectable islet autoantibodies ( mean age 30 years , 40 % females ) , in 12 centers in Germany . Patients received placebo or 80 mg/d atorvastatin for 18 months . As primary outcome stimulated serum C-peptide levels were determined 90 min after a st and ardized liquid mixed meal . For this secondary analysis patients were stratified by single baseline characteristics which were considered to possibly be modified by atorvastatin treatment . Subgroups defined by age , sex or by baseline metabolic parameters like body mass index ( BMI ) , total serum cholesterol or fasting C-peptide did not differ in C-peptide outcome after atorvastatin treatment . However , the subgroup defined by high ( above median ) baseline C-reactive protein ( CRP ) concentrations exhibited higher stimulated C-peptide secretion after statin treatment ( p = 0.044 ) . Individual baseline CRP levels correlated with C-peptide outcome in the statin group ( r2 = 0.3079 , p<0.004 ) . The subgroup with baseline CRP concentrations above median differed from the corresponding subgroup with lower CRP levels by higher median values of BMI , IL-6 , IL-1RA , sICAM-1 and E-selectin . Conclusions / Significance Atorvastatin treatment may be effective in slowing the decline of beta cell function in a patient subgroup defined by above median levels of CRP and other inflammation associated immune mediators . Trial Registration Clinical Trials.gov
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .